Familial intrahepatic cholestasis (ABCB4 gene)

Familial intrahepatic cholestasis related to the ABCB4 gene is a rare hereditary liver disorder caused by pathogenic variants that alter the MDR3 protein. This dysfunction reduces the biliary secretion of phospholipids, generates more toxic bile, and favors cholestasis with elevated GGT, pruritus, jaundice, and progressive liver disease.

Progressive familial intrahepatic cholestasis type 3 (PFIC3) is mainly associated with biallelic variants in ABCB4. This gene encodes the MDR3 protein, a transporter located in the canalicular membrane of hepatocytes that transports phosphatidylcholine into bile. Phosphatidylcholine protects the biliary epithelium from the detergent effect of bile acids; when MDR3 fails, bile becomes deficient in phospholipids and can damage hepatocytes and cholangiocytes, leading to cholestasis, portal inflammation, and progressive fibrosis.

The classical form is inherited in an autosomal recessive pattern, so an affected person usually inherits two altered copies of ABCB4, one from each parent. However, some heterozygous variants have been linked to milder or late-onset phenotypes, such as intrahepatic cholestasis of pregnancy, low phospholipid-associated cholelithiasis (LPAC), or chronic liver disease. The global incidence of progressive familial intrahepatic cholestases is estimated to be around 1 in 50,000-100,000 births.

Symptoms

Symptoms can appear from infancy or early childhood, although milder forms may debut in adolescence or adulthood. The main manifestations include persistent jaundice, intense itching, hepatomegaly, growth retardation, and fat malabsorption with fat-soluble vitamin deficiencies. GGT is usually elevated. Over time, it can progress to fibrosis, cirrhosis, portal hypertension, liver failure, and an increased risk of hepatobiliary neoplasms, such as hepatocellular carcinoma, cholangiocarcinoma, or gallbladder cancer.

Disease management

Management focuses on reducing biliary toxicity, controlling symptoms, and preventing the progression of liver damage. It includes follow-up by hepatology, nutritional support, and supplementation of fat-soluble vitamins (A, D, E, and K). Ursodeoxycholic acid (UDCA) may improve cholestasis, especially when there is residual MDR3 activity. In patients with severe pruritus, fibrosis, or lack of response to medical treatment, other specialized measures may be considered, and in progressive disease or liver failure, liver transplantation.

Genes analyzed

ABCB4 U
U Ultra Whole Genome Sequencing 30x

Bibliography

A Siddiqi I, Tadi P. Progressive Familial Intrahepatic Cholestasis. 2023 Jul 3. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.

Vitale G, Mattiaccio A, Conti A, et al. Genetics in Familial Intrahepatic Cholestasis: Clinical Patterns and Development of Liver and Biliary Cancers: A Review of the Literature. Cancers (Basel). 2022 Jul 14;14(14):3421.

What do your genes say about you? Start your journey today.

Get a special 5% discount on your first kit.

Haven't you taken our DNA test yet?

Get your genetic test and discover what your DNA says about you.

pack
Starter DNA test
The best option to get started

Ancestry service, Traits and Wellness

Buy
pack
DNA test Advanced DNA test
Know your DNA in depth

Health, Ancestry service, Traits and Wellness

Buy
pack
Genetic analysisUltra
Whole Genome Sequencing 30x

Health, Ancestrality, Traits and Wellness

includes three months of tellmeGen+

Buy

Important information and limitations

Europe
Austria
Belgium
Czech Republic
Denmark
Finland
Germany
Hungary
Ireland
Italy
Netherlands
Norway
Poland
Portugal
Romania
Spain
Sweden
Switzerland
United Kingdom
Asia
Kazakhstan
Saudi Arabia
UAE
America
Brazil
Canada
Chile
Colombia
Mexico
Panama
Peru
United States
Oceania
Australia
The Best Prices of the Year! Only until November 27 Use our coupon BLACK15
Buy